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Abstract
Background: Pharmacovigilance (PV) data are crucial for ensuring safety and effectiveness of medicines after drugs 
have been granted marketing approval. This paper describes the PV systems of India, Uganda and South Africa 
based on literature and Key Informant (KI) interviews and compares them with the World Health Organization’s 
(WHO’s) minimum PV requirements for a Functional National PV System.
Methods: A documentary analysis of academic literature and policy reports was undertaken to assess the medicines 
regulatory systems and policies in the three countries. A gap analysis from the document review indicated a need 
for further research in PV. KI interviews covered topics on PV: structure and practices of the system; current 
regulatory policy; capacity limitations, staffing, funding and training; availability and reporting of data; and 
awareness and usage of the systems. Twenty interviews were conducted in India, 8 in Uganda and 11 in South 
Africa with government officials from the ministries of health, national regulatory authorities, pharmaceutical 
producers, Non-Governmental Organizations (NGOs), members of professional associations and academia. The 
findings from the literature and KI interviews were compared with WHO’s minimum requirements. 
Results: All three countries were confronted with similar barriers: lack of sufficient funding, limited number 
of trained staff, inadequate training programs, unclear roles and poor coordination of activities. Although KI 
interviews represented viewpoints of the respondents, the findings confirmed the documentary analysis of the 
literature. Although South Africa has a legal requirement for PV, we found that the three countries uniformly 
lacked adequate capacity to monitor medicines and evaluate risks according to the minimum standards of the 
WHO.
Conclusion: A strong PV system is an important part of the overall medicine regulatory system and reflects on the 
stringency and competence of the regulatory bodies in regulating the market ensuring the safety and effectiveness 
of medications. National PV systems in the study countries needed strengthening. Greater attention to funding 
is needed to coordinate and sustain PV activities. Our study highlights a need for developing more systematic 
approaches to regularly monitoring and evaluating PV policy and practices. 
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Implications for policy makers
• Given that similar barriers: insufficient funding, limited trained staff, inadequate training programs, unclear roles and poor coordination of 
activities confronted the Pharmacovigilance (PV) systems of India, Uganda and South Africa, the use of greater capacity-building within the 
three countries and in other countries with similar levels of healthcare system development would be useful  to coordinate and sustain PV 
activities. 
• Having a clear structure of  legal PV requirements with corresponding regulations in place where compliance and enforcement could be 
ensured, would be more effective than reliance on guidelines and normative practice which are not specifically binding.
• The findings contribute to an area that highlights a need for developing more systematic monitoring and evaluation of PV policy and practices 
on a regular basis (i.e. causality assessment leading to accurate signal detection).
Implications for public
A strong Pharmacovigilance (PV) system is an important part of an overall medicines regulatory system in ensuring safety and effectiveness of 
medicines. It reflects the stringency and competency of regulatory bodies in the regulation and control of products on the market. The World Health 
Organization (WHO) has established core minimum requirements for a functional national PV system. Results from a documentary literature 
search and information obtained from interviews with authoritative officials, professionals and other stakeholders, concluded that only South Africa 
had a legal requirement for PV and that India, Uganda and South Africa uniformly lacked adequate capacity to monitor medicines and evaluate 
risks according WHO’s standards. Good PV will identify risks associated with medicines in a minimum amount of time and when effectively 
communicated, will allow for intelligent, evidence-based use of medicines having the potential for preventing many Adverse Drug Reactions 
(ADRs). The review of national PV systems against the WHO’s core minimum requirements has proven an effective way to assess the adequacy of 
such systems. The World health Assembly should use its law making powers to strengthen and make mandatory PV activities in the interests of 
public health.
Key Messages 
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Background
The importance of Pharmacovigilance (PV)
Pharmacovigilance (PV) data are vital to ensure on-
going safety and effectiveness of medicines and to provide 
information concerning regulatory actions such as drug safety 
alerts, labelling changes to the product information, drug 
recalls or withdrawal of a drug from the market. PV is defined 
by World Health Organization (WHO) as: “The science and 
activities relating to the detection, assessment, understanding 
and prevention of adverse effects or any other possible drug-
related problems” (1). 
Good PV will identify risks associated with medicines in a 
minimal amount of time and when communicated effectively, 
information will allow for intelligent, evidence-based use of 
medicines which will have potential for preventing many 
adverse reactions. WHO and its regional offices play a key 
role in supporting countries in promoting the establishment 
and building of sustainable monitoring systems. It serves 
as a repository for PV information and disseminates this 
information appropriately. Under coordination of the 
WHO and its Collaborating Centre for International Drug 
Monitoring [the Uppsala Monitoring Centre (UMC) in 
Sweden], are national centres collecting reports of suspected 
Adverse Drug Reactions (ADRs) (2). After review, they are 
sent to UMC for entry into the database which generates 
signals of previously unrecognized ADRs. The integration of 
PV is crucial to the success of public health programs using 
medicines (3). 
National PV and ADR reporting systems in India, Uganda 
and South Africa are in their infancies and are not yet 
functioning optimally (4,5). This is due to lack of human, 
technical and financial resources (2,6). According to 
the WHO, in many developing countries patients are 
not adequately safeguarded from accessing harmful and 
ineffective medicines due to poor PV systems (1). This may 
result in treatment failures. Particular attention needs to 
be paid to proper infrastructure and governance, adequate 
human resources, training and capacity-building and 
sustainable methodologies and innovation in PV (6). In 2010, 
the WHO in consultation with its Advisory Committee on the 
Safety of Medicinal Products (ACSoMP) and the Global Fund 
to Fight AIDS, Tuberculosis and Malaria (GFATM) agreed on 
the core the minimum requirements that should be present 
for a functional national PV system (7). 
1. A national PV centre with designated staff (at least one 
full time), stable basic funding, clear mandates, well-
defined structures and roles and collaborating with the 
WHO Programme for International Drug Monitoring;
2. A national spontaneous reporting system in existence 
with a national ADR reporting form;
3. A national database or system for collating and managing 
ADR reports;
4. A national PV advisory committee that is able to 
provide technical recommendations on safety issues and 
regulatory actions; validate causality and evaluate risk; 
and when necessary, participate in crisis management 
including crisis communication;
5. A communication strategy that is clear for both routine 
and crises communication.
In 2011, a PV Toolkit was developed and maintained by 
the WHO Collaborating Centre for Advocacy and Training 
in PV, University of Ghana Medical School on behalf of the 
WHO Programme for International Drug Monitoring and 
in collaboration with the WHO, UMC and ACSoMP. It is a 
package of simple PV tools and a description of supporting 
processes for the conduct of PV (8).
Our study was conceived in the framework of the AMASA 
(Access to Medicines in Africa and South Asia) project (http://
www.amasa-project.eu/). Similar research had previously 
been carried out in India and Nepal. To assess the relevance 
of findings in other low- and middle-income settings of 
South Asia and Africa, we compared the situation in a large 
Indian state, Maharashtra, and in two African countries –
South Africa, which had substantial production capacity, 
and Uganda which had very limited production capacity. By 
exploring the regulatory systems and policies in the three 
countries the effectiveness of PV needed to ensure access 
to quality medicines could be evaluated. Examining and 
comparing elements of the three PV systems with reference to 
the WHO’s minimum requirements provides an opportunity 
to clarify and address limitations of PV and how these affect 
access and indicate challenges for informed policy-making in 
these countries and beyond. 
 
Aim
This study aimed to describe the PV systems in India, Uganda 
and South Africa. It also aimed to analyse the extent to 
which the three countries conformed to the minimum PV 
requirements by the WHO. 
Methods
Study design
Background to study work on Access to Medicines in Africa and 
South Asia (AMASA) 
A documentary analysis of academic literature and policy 
reports covering the time period 2005–10 was undertaken 
to: 1) assess the medicines regulatory systems and policies 
in India, South Africa and Uganda; and 2) to understand the 
overall pharmaceutical regulation by looking at regulatory 
structures and key bodies involved in the process for 
regulating medicines. The review focused on pharmaceutical 
regulation, which includes regulatory frameworks and 
capacity; use of medicines; and PV, including descriptions 
of the adverse event reporting systems. A gap analysis of 
the literature indicated a need for further research of the 
PV systems. An interview guide was designed as the part of 
the AMASA project for Key Informant (KI) interviews and 
included questions on regulatory systems and policies with 
regard to PV in the three counties. 
World Health Organization’s (WHO’s) Pharmacovigilance 
(PV) Framework
The WHO has defined minimum requirements, norms 
and standards for a functional national PV system (7) and 
provides a clear authoritative framework for countries 
developing a PV system (2). This framework was used as a 
basis for analysing the PV systems in the three countries. 
WHO is involved in activities to strengthen country initiatives 
in PV and safety monitoring. The WHO UMC coordinates 
the WHO Programme for International Drug Monitoring 
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(9). After review of the safety reports, they are entered by the 
national centres into – VigiBase™ – a database maintained 
and developed by UMC on behalf of the WHO. The WHO 
Uppsala monitoring program recommends that, ideally, a 
national PV centre should send over 200 reports per million 
inhabitants per year (2,10). 
Literature review process
Country-specific regulations, policies and guidance for PV 
were retrieved at the country level using Medline/PubMed, 
Google Scholar, and ISI Web of Knowledge) for the period 
2005–10 by local researchers in India, Uganda and South 
Africa. Global literature on PV was also retrieved. Search 
terms included: PV, post-marketing surveillance, drug safety, 
developing countries, India, Uganda, South Africa and WHO. 
An additional literature search was conducted following the 
gap analysis. All the retrieved literature was managed through 
Reference Manager software.
Key Informant (KI) interviews
The interviews conducted in the three countries were 
part of research activities for the AMASA project which 
included topics covering access to medicines: production, 
procurement, regulatory practices, PV, counterfeit medicines, 
drug advertising, interactions with policy-makers and 
supply chain issues. The questions focusing on PV included: 
structure and functioning of the program and its challenges, 
implementation of the system, funding, staffing and training, 
issues on availability and reporting of data, and awareness 
and usage of the system. In order to obtain information which 
was not available in the literature review, the respondents 
interviewed included high level government officials from the 
health ministries, national regulatory authorities, members of 
trade and industry associations, academics, pharmaceutical 
producers and Non-Governmental Organizations (NGOs) 
who were knowledgeable and experienced in these areas. 
The information provided by the respondents represented 
their viewpoints, based on their experience. It was agreed 
with the respondents that information they provided would 
be kept anonymous. The collected information would be 
coded and respondent names would not be disclosed. Twenty 
interviews were conducted in India, 8 in Uganda and 11 in 
South Africa. Ethical clearance was obtained in each country 
prior to start of the research. The ethical guidelines and 
procedures were on par with those of the European partners 
as well as the European Union (EU) directives on the ethical 
review process. Informed consent in writing was obtained 
from each respondent and each respondent received written 
information explaining the research prior to participating in 
the research project. 
Data management, analysis and dissemination
The interview data was collected using an interview guide. 
Information from KI interviews was transcribed locally. The 
interviewer undertook a quality check of the transcriptions. 
Thematic coding was based on issues identified in the KI 
interview guide, and these were coded in MAXQDA software 
by research managers from the three study countries. A lexical 
search for key words to identify and code additional thematic 
content from the study was performed. 
After reviewing the literature and considering the KI 
interviews, we formatted a strategy to compare the PV 
systems of the three countries to the WHO standards. We 
coded the data sets. The information is presented by country 
and summarized in Table 1 in the Results. Key findings from 
the countries were presented at a Dissemination Meeting 
in London in September 2013. Key opinion leaders from 
the three countries and WHO were present who actively 
participated in a panel discussion. 
Results
The findings for the three countries are separated into: 1) the 
literature review; and 2) the KI interviews.
India’s pharmacovigilance (PV) system
Literature review
In India there was no legal requirement to make PV reporting 
mandatory. Post-marketing surveillance relied on voluntary 
reporting. Requirements and guidelines for PV in India 
were set out in amendment 2005 to Schedule Y of the Drugs 
and Cosmetic Act (11). It defined the responsibilities of 
pharmaceutical companies for their marketed products, 
as well as responsibilities for reporting adverse events 
from clinical trials and although not explicitly defined, the 
language was consistent with WHO’s definition of  PV. A 
pharmaceutical company holding a product license in India 
must ensure that it had in place an adequate PV system 
including establishment and maintenance of appropriate 
systems to collect collate and evaluate information about 
suspected adverse reactions. Although not stated in the 
law, the Periodic Safety Update Report (PSUR) should be 
submitted by a pharmaceutical company for a product 
marketed in India. All pharmaceutical companies were 
required to keep records of ADR reports from marketed drugs 
and from clinical trials. They were reported to the All India 
Institute of Medical Sciences (AIIMS) in Delhi. Companies 
also reported the ADRs to their parent companies via their 
internal reporting systems. 
Attempts had been made since 1986 to introduce a national 
PV system in India. The latest Pharmacovigilance Programme 
for India (PvPI) for assuring drug safety was implemented 
in 2010. The Central Drugs Standard Control Organization 
(CDSCO), Directorate General of Health Services under the 
sponsorship of the Ministry of Health and Family Welfare 
(MHFW), government of India collaborated with the Indian 
Pharmacopoeia Commission (IPC), Ghaziabad, to coordinate 
the PvPI (12,13). Despite the new PvPI, PV activities remained 
under-funded (13).
The IPC which is an autonomous institution under the 
MHFW also collaborated with the WHO UMC for technical 
support and to establish the National Coordinating Centre 
(NCC) AIIMS (12). Targets were set for each of its 5 phases 
and would continue through 2015 (12). The state drug 
regulatory authorities were not involved in the PV activities. 
The Medical Council of India assumed responsibility for the 
PvPI. It was proposed that every medical college in India 
should have a PV department of which the vast majority of 
monitoring centres were in government medical colleges. 
The three levels of reporting included tertiary centres which 
reported to the secondary centres which reported to regional 
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centres. The regional centres reported to NCC – AIIMS and 
gave input to the WHO. In India the reporting of ADRs was 
passive. PV centres were recently established in private sector 
hospitals (12). Figure 1 indicates the communication pathway 
of ADRs in India.
The PvPI guidelines stated that physicians, pharmacists and 
healthcare professionals should report all suspected ADRs 
on a designated form for submission to CDSCO. India’s 
ADR form was evaluated in a study assessing data capture. 
Of 18 points which were considered to make a good ADR 
report, India received thirteen points (14). The International 
Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH) 
Guidelines also requires that ADRs are reported during 
clinical trials. However, with regard to the general population, 
poor consumer awareness of the need to report ADRs 
remained an issue due to a lack of knowledge (15).
India had a formal ADR monitoring system in place since 
1986; however a project funded by World Bank revealed that 
no ADRs had been reported for a period of over 10 years and 
data which had been collected were never analysed. Much had 
been attributed to financial inconsistencies (13). Previously, 
PV had been an externally funded activity. The government 
had been given a small budget to set up the PV system but this 
proved impossible for a country the size of India. PV was then 
positioned in the budget of the Ministry of Health (MoH).
The reporting rate for ADRs was low. India, with its 
population of approximately 1.24 billion, had a rate of PV 
reporting below 1% (4). This low rate was attributed mostly 
to the lack of training of physicians and pharmacists, and to a 
poor initiative in reporting ADRs (16). Approximately 45,000 
ADRs had been collected, collated and communicated to 
WHO – UMC which was about 18,000 reports per year from 
July 14, 2010, when PvPI was launched, through December 
2012. The ADR reporting rate for 2011 was approximately 15/
million population (9,17).
Key Informant (KI) interviews
The head of an ADR monitoring centre stated that resources 
were not viewed as problematic and that human resources, 
journals, electronic databases and drug information were 
available in Mumbai. In contrast, outside of Mumbai there 
were not enough computers; internet connections were 
frequently lacking and power outages occurred. 
A clinical pharmacologist at an ADR Monitoring Centre 
stated that in some cases, health managers had no idea about 
the PvPI and the CDSCO did not keep track of the data due to 
a lack of human resources. The head of clinical pharmacology 
at another monitoring centre described that oftentimes 
the CDSCO had not reviewed the PSUR submitted by the 
pharmaceutical company so there was a lack of feedback or 
there was no time to track the post-marketing surveillance. 
When medical representatives from companies received 
feedback from the analysed data, it was not known what had 
been done with the data. 
The Head of an ADR monitoring centre described that the 
previous system depended totally on the poor spontaneous 
reporting from doctors in Mumbai. However, the new 
reporting system was also viewed as weak: “Pharmacists are 
not well-educated about the PvPI and do not or rarely report 
ADRs or see that they play a role in reporting ADRs”.
At one regional centre the situation was different and future 
physicians were being trained in ADR monitoring. Students 
were exposed to the ADR reporting form as undergraduates. 
Physicians and students were making rounds together to 
monitor patients. Teams were discussing possible ADRs and 
help was available for physicians. These factors seemed to be 
motivating the physicians. 
Although big hospitals or centres of excellence had PV 
systems in place, the reporting guidelines were often unclear 
and cases were often described without further follow-up. 
An informant explained, as follows: “Patients frequently 
do not know what medicines they have taken and cannot 
provide accurate information regarding an ADR. It is not 
known whether Standard Operating Procedures (SOPs) are in 
place or how the information are categorized and processed. 
Doctors often receive information about adverse drug effects 
from patients and do not have time or are not interested in 
submitting spontaneous reports. Doctors are afraid that if they 
report side effects of drugs, they will lose their credibility and 
will be perceived as prescribing drugs that harm the patient”. 
A local affiliate of a large multinational pharmaceutical 
viewed the new system as a major initiative and thought 
PV would become stronger in India. ADR reports from the 
Indian population could be analysed and as a result, necessary 
safety and regulatory decisions could be applied to the 
Figure 1. Adverse Drug Reaction (ADR) communication channels in India. 
WHO/Uppsala Monitoring Centre (UMC) 
ADRs:  
Patients,  
Pharmaceutical industry, 
Healthcare professionals 
PvPI National Coordinating Centre India Pharmacopoeia 
Commission Ghaziabad (AIIMS) 
PvPI ADR Monitoring Centres  
in Medical Colleges 
Central Drugs Standard Control Organization (CDSCO) 
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Indian population. 
Uganda’s pharmacovigilance (PV) system
Literature review
Under the National Drug Policy and Authority (NPD & A) 
Act (1993) the Uganda National Pharmacovigilance Centre 
(NPC) is responsible for PV efforts in the country and 
mandates the National Drug Authority (NDA) to monitor 
the safety, efficacy and quality of medicines. The NPD & A 
did not specify PV as a law (18). A legal provision mandating 
PV and regulations was lacking and a strategy to coordinate 
stakeholders involved in PV needed developing (10,18). The 
reporting of ADRs was voluntary for health providers. A 
draft regulation in 2011 had proposed mandatory reporting 
of ADRs for industry and healthcare workers (19). It was 
mandatory for principal investigators of clinical trials to 
report ADRs based on the “Guidelines for Conducting 
Clinical Trials” from the National Council of Science and 
Technology.
The MoH was involved with the PV program at the NDA. 
The NDA acted as a coordinator and conducted PV surveys. 
The NPC was one of four core departments reporting to the 
Executive Secretary/Registrar of NDA and was responsible 
for managing and co-coordinating PV. 
The Drug Information/PV Department of the NDA 
supervised the NPC activities via facilities at eight regional 
referral hospitals of university teaching hospitals. Not all 
regional PV centres were actively engaged in collecting 
and reporting ADRs. Consistent training was required to 
encourage centres to increase the reporting rate (10). 
The Committee on PV and Clinical Trials participated in 
monitoring effects of medicines (20). A national PV guideline 
had been developed and distributed to stakeholders (10). 
Figure 2 illustrates the flow of ADR information in Uganda.
A generic form was used for reporting ADRs and it was 
available in most big hospitals. The NDA, MoH and 
practitioners cooperated together in PV activities. However, 
the PV database contained partial sources of information 
(10). In 2009 the reporting rate was 6 ADRs per million 
population (19) [approximately 30.6 million population 
in 2009 (21)]. 
The NDA had a department supported by technical staff. The 
NPC had regular technical support from the WHO country 
office and shared information with the WHO UMC. Eight 
staff managed PV issues within the Drug Information/PV 
Department (19). 
The NPC was recently experienced in managing risks and 
communication. Signal generation and risk evaluation 
needed to be strengthened. A structured procedure on risk 
management and risk communication especially for high 
risk medicines needed to be developed (18,20). Although 
NPC published newsletters about PV-related activities, press 
releases, and safety alerts for dissemination of information, 
effective communication was still a challenge (10). 
There was a very limited amount of financial support 
dedicated for PV and it was calculated to be <1.0% of the 
NDA’s budget for 2011–12 (18). 
Key Informant (KI) interviews
A representative of the Pharmaceutical Society of Uganda 
remarked that it was often difficult to obtain ADR reports 
even in public centres due to the low reporting rate; it was 
a challenge to have the PV system operating smoothly. ADR 
data were not recorded for many products. The reporting task 
was perceived as additional work due to all of the forms that 
needed to be completed. 
Money to support PV was being obtained from donors 
e.g. East African Community, WHO, the United States 
Food and Drug Administration and from the government. 
Funding for the PV program was insufficient. The NDA had 
tried to incorporate PV into educational programs and the 
concept was currently being included in the curriculum of 
medical schools. 
Outpatient centres were rarely reporting ADRs and reporting 
forms were not always available. The private sector perceived 
collecting ADRs as extra work and therefore were reluctant to 
report events. A local company representative stated: “There 
is no active PV system in Uganda”. It used its own SOP for PV 
and was conducting its own surveillance.
A senior official of the NDA explained that software provided 
by WHO was complicated. When the data were not fully 
entered, the software refused the entry. This discouraged 
those who wanted to submit reports and the number of 
reports filed had been declining. 
Figure 2. Adverse Drug Reaction (ADR) communication channels in Uganda. Abbrivations: NPC= National Pharmacovigilance Centre; NDA= 
National Drug Authority; PV= Pharmacovigilance; MoH= Ministry of Health.
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Although staff were being trained through a national training 
program, there were not enough practitioners to report 
ADRs. Practitioners may have been interested in PV but there 
was little incentive for active reporting. The representative of 
the Pharmaceutical Society remarked that some practitioners 
had not yet heard of the program. 
Oftentimes people had a fear of litigation if they would have 
been asked to testify as a witness in court cases involving 
medical malpractice. However, for reporting ADRs a toll-free 
number had been installed in Kampala and in the rural areas; 
an SMS system was being developed. On FM radio stations 
there was information on PV which was being transmitted in 
the local language to various regions. 
South Africa’s pharmacovigilance (PV) system 
Literature review
PV is a function of the Medicines Control Council (MCC), the 
regulatory authority in South Africa. Since 1997, Regulations 
34 and 37 of the Medicines and Related Substances Control 
Act, Act 101 of 1965 as Amended (Act 90) (22) required that 
the marketing authorization holder report all adverse events, 
ensure safe use, and collect real-life safety and effectiveness 
data on a product (10,22).
The MCC had in place the National Adverse Drug Event 
Monitoring Centre (NADEMC) at the University of Cape 
Town which was responsible for collating data on the ADR 
reports and assessment of causality and risk of ADRs. ADRs 
were reported from the NADEMC to the MCC. Spontaneous 
ADR reports on antiretroviral drugs were collected solely 
by the Medicines Information Centre. There were other 
institutions following up on signals from spontaneous ADRs 
but they were working independently and information was 
not being fed into the national system. Other parallel systems 
existed for public health programs and NGOs but data were 
not being fed centrally. 
The MCC’s PV Committee was comprised of a pharmacist 
and six external experts from various institutions who 
made up the PV Advisory Committee. It reviewed 
complaints and ADRs and could make recommendations 
to the MCC regarding the registration conditions of the 
specified medicines which included enforcing withdrawal 
of a medicine from the market and requiring updates to 
the product information to ensure public safety. It had also 
drafted guidelines for industry on ADR reporting. The 
Clinical Committee became involved if a labelling change 
was required. 
The office of the Registrar, the Medicines Regulatory Affairs 
(MRA), a Chief Directorate within the Department of Health, 
provided administrative and technical support to the MCC. 
The Deputy Director for PV was located within a Directorate 
of the MRA. Since 2006, in-house regulatory capacity had 
become an issue in the MRA due to increased workload and 
many regulatory evaluations were done by PC members.
Pharmaceutical companies worked closely with the NADEMC 
and ADRs were reported from the NADEMC to the MCC. 
Spontaneous reports were received from the public, doctors, 
and pharmacists. The ADR reporting form was also evaluated 
in a study assessing data capture. Of eighteen possible points 
considered to make a good ADR report, South Africa’s form 
received a score of twelve (14). 
Companies were required to submit PSURs at specified 
intervals following approval of a drug. The MCC required 
a company employ a dedicated PV specialist (pharmacist or 
nurse). Figure 3 shows ADR reporting in South Africa.
The WHO UMC advised that the ADR reporting rate for 2010 
was 58/million population (2,902 ADR reports). For 2011 the 
ADR reporting rate was 77/million population (4,088 ADR 
reports) (23). The population of South Africa in 2010 was 
approximately 50.1 million (24); in 2011 was approximately 
51.8 million (25). Data are often not available or are under-
reported compared with other countries (5).
Key Informant (KI) interviews
Several KIs reported that PV activities were fragmented and 
that duplication existed. The NGOs were not coordinating 
with the national system and there was under-reporting for 
Tuberculosis (TB) and anti-retroviral (ARV) drugs. Much of 
the data that had been collected went directly to the NADEMC 
where there was insufficient capacity for analysis.
Lack of manpower was identified as the biggest challenge. 
A chief pharmacist was working for NADEMC with no 
administrative staff. Two other chief pharmacists, three 
principal pharmacists and five administrative staff at other 
locations were working for the National PV Program (NPP) 
under the coordinator (Deputy Director). 
Recruitment of staff for open positions at the NADEMC was 
Figure 3. Adverse Drug Reaction (ADR) communication channels in South Africa. MCC= Medicines Control Council.
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very slow and a work backlog of three years existed which 
was mainly attributed to bureaucratic delays. It was very 
difficult to find high calibre people in the provinces as PV was 
perceived as an administrative task. In the future, the NPP 
was expected to produce many officers, additional training, 
and a training manual and post graduate courses. 
There was no separate budget for PV or meta-analysis 
and epidemiological studies although it was understood 
that provision was made for funding requests through 
MRA. External experts on the PC were remunerated on an 
hourly basis.
A decentralized PV Plus Program was being planned for the 
future and clinical interventions from spontaneous reports 
would be immediately implemented when necessary. Safety 
information was to be cascaded through other countries 
and resources would be pooled at a very low cost using the 
existing infrastructure. Most interventions (e.g. amended 
labelling and recalls) were a result of safety data from 
international warnings.
For voluntary reporting healthcare professionals used the 
standard ADR form available on the MCC website which was 
viewed by users as cumbersome. Although other forms were 
accepted, they would often lack sufficient information, often 
omitting patient details required to track a report. 
There was no distinction between the public and private 
sectors. Reporting was generally low but had increased in 
the public health sector with more ARV report submissions. 
Private sector reporting, including private pharmacies was 
considerably less than in the public sector. Reports from 
consumers had increased but were not encouraged due to 
their poor quality and were received mainly from patient 
support groups or via pharmacies. Poor reporting was also 
attributed to lack of commitment by health professionals. 
Private pharmacies made few reports. The NPP identified a 
need for active surveillance where ADRs could be identified 
and investigated over a defined period of time Cohort 
monitoring was done by independent research units and 
information was not fed into the national system.
Mandatory reporting came from industry as companies 
were obligated to investigate ADRs. As no guidance existed, 
reporting was usually done on a case by case basis. One 
company reported that it did not have capacity to report ADRs 
electronically and relied on the MCC to manage the data. 
Faxing ADR reports to the NADEMC was the preferred 
method of submission. When reports were sent electronically, 
they created an overload in the system. Data were captured 
manually and processed slowly. A new Electronic Data 
Management System (EDMS) was under discussion by MCC 
and was expected to soon be in effect.
Data were captured as individual reports and a line listing 
was produced for every PV meeting. Databases used by 
public health programmes, NGOs and NADEMC were not 
compatible and data were difficult to access and analyze. 
Feedback on submitted ADR reports were lacking and the 
MCC were reluctant to provide information on reporting rates 
to the provinces, not wanting provinces to make a decision 
from a signal based on spontaneous reporting. It appears that 
quantifiable reporting rates were lacking for ADRs. An MCC 
member stated: “Reports are shared only within the MCC. The 
Registrar is very reluctant to give any information as it may be 
interpreted incorrectly. The numbers of reports can be shared 
with other regulatory authorities but not specific information 
on individual drugs”.
An official from MCC revealed that due to lack of manpower 
only serious ADRs were reported to the company and the PC 
did not have the capacity or desire to be involved in the pre-
approval process or risk analysis. 
A regulator from the MCC commented: “International 
coordination is not functioning well and PV is treated as a local 
issue. Local ADRs are not often monitored and the Committee 
depends on data from “E-drug” and occasionally the media. PV 
is exclusively post-approval. It is mainly spontaneous reporting 
and from signals received from the USFDA and EMA (European 
Medicines Agency) although contacts are not as strong as they 
used to be since the MCC is so slow to respond”. The MCC 
regularly sent out warning letters concerning ADRs for 
specific drugs but oftentimes information came from other 
countries. 
A provincial department of health official in the 
pharmaceutical services disclosed that medicine safety issues 
communicated in the media resulted in an influx of reports 
on a particular medicine due to the attention they generated. 
Doctors explained that they did not receive feedback from the 
MCC concerning reported ADRs while the MCC claimed that 
there were too many reports on which to provide feedback. 
Most interventions which resulted in changes in the labelling 
or product recalls were communicated through a “Dear 
Healthcare Professional” letter or via a “medical safety alert” 
in local journals. A drugs or therapeutics bulletin did not exist 
and the MCC did not have a public relations officer. Drug 
safety alerts were not sent out. The website of the MCC was 
not always functional so it was difficult to obtain information. 
Summary of Pharmacovigilance (PV) systems
Table 1 presents a summary of the findings from the literature 
and KI interviews in the three study countries during the 
study period. The table compares the conformance of the 
countries to WHO’s standards. The information was cited 
in: 1) the literature; 2) KI interviews; 3) both; or 4) lacking 
in both.
Discussion
Although all three countries had national PV systems 
in place, none had the capacity to adequately monitor 
medicines and evaluate risks. Only South Africa had a 
legal framework in place requiring that adverse events be 
monitored both actively and passively. India should make its 
post-marketing surveillance legally mandatory and should 
not have relied solely on voluntary reporting. Uganda was 
limited in enforcing its monitoring policies without a legal 
provision. Placing legal obligations on industry to report to 
authorities and authorities to pool data within one country or 
internationally is standard practice in high income countries 
but few countries place a legal obligation on healthcare 
professionals to report ADRs. It is questionable as to whether 
this has demonstrated an increase in reporting. Having a 
clear structure of legal requirements with corresponding 
regulations in place would ensure stronger compliance and 
enforcement rather than relying on guidelines and normative 
practice which are not specifically binding. 
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Key deficiencies in all three countries were: lack of sufficient 
funding and capacity; limited trained staff and training 
programs; unclear roles; and poor coordination of activities. 
Although the WHO’s country offices and UMC provided 
collaboration for technical support, more support was needed 
in order that collected data could be adequately analysed. The 
WHO minimum requirement of one full time designated 
staff was insufficient to operate a national PV centre and 
highlighted a problem with the guidance. 
Based on the literature the MCC in South Africa wanted to be 
seen as being active in PV but the KI interviews revealed that 
its system was lacking a well-functioning infrastructure to 
effectively collect and evaluate safety data in a timely manner. 
Insufficient funding was a recognised problem in all three 
countries. Budgets were inadequate to meet the needs 
for effective operation of the systems. Additional funds 
were required for training of healthcare professionals and 
for development of educational programs in PV in the 
public sector. 
The topic PV was not well-integrated into the curricula in 
medical, pharmacy and nursing schools. However, a regional 
centre in India was exposing future physicians to the concept 
of ADR monitoring which was a motivating factor. In Uganda 
PV was included in the curriculum of medical schools. In 
South Africa there were plans for additional training in 
PV and post graduate courses. The countries were in need 
of continuous support for their efforts if their PV systems 
were to improve.
Pharmaceutical companies were a major focus of PV 
activities. Through the submission of PSURS and reporting 
of serious ADRs within a specified timeframe, companies 
were required to comply with the regulatory requirements for 
reporting ADRs to the national PV centres. The local head 
of a multinational pharmaceutical company in India who 
viewed India’s new system as positive thought that the effects 
of India’s new program would directly benefit the Indian 
population in the future. To achieve this, it was crucial that all 
pharmaceutical companies be held accountable for reporting 
ADR data.
Reporting rates were low in all three countries. This was 
attributed to lack of capacity, insufficient funding, insufficient 
training for healthcare professionals and regulators, and for 
complex software and overloaded systems. Low reporting 
rates made it difficult for the effective detection of signals, 
evaluation of risks, and taking necessary regulatory actions. 
Even though reporting rates were too low, the number of 
ADR reports was increasing. This indicated that although 
there was progress, the countries were still struggling with 
their systems. In all three countries reporting forms did not 
appear to be standardized, were viewed as cumbersome and 
therefore contributed little incentive for completion, all of 
which were problematic. 
Advisory committees were adversely affected due to lack 
of capacity and technical training. It was difficult for them 
to accurately assess causality. These factors contributed to 
difficulties in communicating recommendations on safety 
issues and regulatory actions to healthcare professionals and 
the public. In Uganda, there had been recent experience in 
managing risks and communication which demonstrated 
progress. The decentralized PV Plus Program that was 
planned for South Africa was expected to improve the flow 
of safety information. However, the ability of an advisory 
committee to provide a clear strategy for routine and crisis 
communication would be negatively impacted without 
adequate human capacity and technical training. 
Without clear communication, a poor awareness of healthcare 
issues would prevail on the part of healthcare professionals, 
industry and consumers. Initiatives like the toll-free 
number and SMS system for reporting ADRs in Uganda 
and information broadcast on the local radio stations would 
increase the confidence in the healthcare system.
Other reviews have compared PV systems in Asia (26). 
Our study has compared these systems in Africa and South 
Asia but with an explicit focus on the WHO minimum 
requirements. The deficiencies that our study identified 
confront low- and middle-income countries which are less of 
a constraint in developed countries. 
Our study relied heavily on KI interviews with authoritative 
officials, professionals and other stakeholders who had 
relevant experience in PV. The KIs represented stakeholder 
interests of health ministries, national medicines regulatory 
authorities, professional organizations, drug manufacturers, 
academics and NGOs. Collectively they represented various 
interests and perspectives with regard to PV, but the depth 
and quality of their interview responses depended on their 
interest and willingness to engage thoughtfully in the 
interview. Recognizing this limitation, we attempted to 
identify a range of these stakeholders to enable us to assess 
the consistency and diversity with reference to source of 
interview data. Nevertheless, details concerning those 
of budget and staff were not uniformly available. Details 
regarding the composition and functioning of the national 
pharmaceutical advisory committees were also limited. Such 
limitations identified in the course of the study highlight 
a need for developing more systematic approaches to 
monitoring and evaluation of PV policy and practices on a 
regular basis. 
The findings from the KI interviews generally confirmed the 
documentary analysis of the literature although information 
from the KI interviews often provided greater detail. Major 
contradictions between the literature and KI interviews 
were not identified. In the KI interviews one instance was 
identified where there was conflicting information regarding 
the need for an increase in human resources.
Conclusion 
The need for a critical analysis presented in this paper was 
indicated to determine if WHO’s minimum requirements 
regarding PV were being followed by the three countries 
during the indicated timeframe. A strong PV system is an 
important part of the overall medicines regulatory system, 
indicating the rigor and competence of the regulatory bodies 
in fulfilling their responsibilities for oversight of producers 
and markets. Although they had some degree of policy and 
guidance, India and Uganda did not have a legal framework 
conforming to WHO’s international recommendations. 
Reporting systems also needed to focus more on active 
surveillance. Better designed, user-friendly, standardized 
reporting forms would improve the process of capturing 
accurate information, including data from spontaneous and 
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active reports, and safety reports from clinical trials with 
reference to WHO standards. 
To achieve these goals, PV needs more particular attention 
in health science curricula. More training is needed for 
healthcare professionals and the local pharmaceutical 
industry. Organizational structures should be strengthened. 
More funding is required to coordinate and sustain activities. 
Separate budgets earmarked for PV should be allocated and 
limitations of human resource capacity in healthcare systems 
must be overcome. 
Inasmuch as the number of ADR reports is increasing, the 
formulation of WHO standards provides a tool that suggests 
prospects for improving the effectiveness of PV. Systems 
for monitoring and evaluation should be implemented to 
monitor the status and progress in the three study countries 
with reference to our findings, and implemented elsewhere to 
enable and promote adherence to basic requirements. 
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